The serotonin type 3 (5-HT 3 ) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT 3 receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT 2 ) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT 3 receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na þ -inward currents through 5-HT 3 receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT 3 receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca 2 þ influx, measured as a change in intracellular Ca 2 þ concentrations ([Ca 2 þ ] i ). All neuroleptic drugs, but not risperidone, antagonized Na þ -and Ca 2 þ -inward currents evoked by 5-HT (10 lM for 2 s and 1 lM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC 50 values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT 3 receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na þ and Ca 2 þ currents. Since 5-HT 3 receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT 3 receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs.
Introduction
Serotonin (5-HT) receptors constitute a complex receptor group with at least seven families comprising 14 structurally and pharmacologically distinct mammalian subtypes. 1 They are mostly G-protein-coupled metabotrobic receptors but one member of this family, the serotonin type 3 (5-HT 3 ) receptor, is a ligand-gated nonspecific, nonselective cation channel.
2 Activation of 5-HT 3 receptors causes membrane depolarization and an increase in intracellular Ca 2 þ . 3 Postsynaptic 5-HT 3 receptors are present on g-aminobutyric acid (GABA) ergic interneurons, mediating fast synaptic neurotransmission in the CNS, 4 ,5 while presynaptic 5-HT 3 receptors modulate the release of several neurotransmitters in various brain regions. 2,6-10 Since 5-HT 3 receptors are highly expressed in the caudate nucleus, putamen, hippocampal and amygdala regions, 1, 7 it has been suggested that selective 5-HT 3 receptor antagonists may have psychotropic effects. 11 Early animal studies suggest that 5-HT 3 receptor antagonists, in addition to their well-recognized antiemetic use, might be clinically useful for the treatment of anxiety, schizophrenia, drug and alcohol abuse, depression, cognitive disturbances, Alzheimer's disease, cerebellar tremor, Parkinson's disease treatment-related psychosis, treatment of inflammatory pain and appetite disorders. 1, 7, 11 The dopamine hypothesis of schizophrenia suggests an enhanced mesolimbic activity of dopaminergic neurotransmission. 12 Behavioural, neurochemical and electrophysiological investigations indicate that 5-HT 3 receptors modulate dopaminergic activity in mesolimbic and nigrostriatal pathways. 1 5-HT 3 receptor activation increased dopamine release from slices of rat nucleus accumbens 13 and striatum. 14, 15 Vice versa, 5-HT 3 receptor antagonists induced a significant reduction in the number of spontaneously active dopaminergic neurons in the ventral tegmental area and substantia nigra compacta, 16 and attenuated dopamine-mediated hyperactivity of the nucleus accumbens. 17, 18 This profile suggests that 5-HT 3 receptor antagonists mimic certain inhibitory effects of neuroleptic drugs on the dopaminergic system and prompted their use in schizophrenia. 7, 19 However, clinical trials with specific 5-HT 3 receptor antagonists as a monotherapy were not encouraging so far. 20 Most neuroleptic drugs are antagonists at dopamine type 2 (D 2 ) and type 4 (D 4 ) receptors. Moreover, neuroleptics exert antagonistic effects at serotonin type 2 (5-HT 2 ) receptors, histamine receptors, muscarinic acetylcholine receptors and a-adrenoceptors. 21 With the exception of clozapine, 22, 23 an interaction of neuroleptics with the 5-HT 3 receptor has not been described so far. If neuroleptics are functional antagonists at 5-HT 3 receptors, this might contribute to the pharmacological profile of these antipsychotic agents. Therefore, we studied whether neuroleptics exert antagonistic effects at endogenous neuronal 5-HT 3 receptors and at human 5-HT 3A receptors stably expressed in human embryonic kidney (HEK) cells.
Material and methods

Chemicals and drugs
The following compounds were used: 5-HT (Sigma, Deisenhofen, Germany), ondansetron (GlaxoWellcome, Bad Oldesloe, Germany), flupentixol, haloperidol, levomepromazine, risperidone and fluphenazine (RBI, Kö ln, Germany), thioridazine (Tocris, Köln, Germany), clozapine (generous gift from Novartis, Nü rnberg, Germany) and phenothiazine, 2-(trifluoromethyl)-phenothiazine and acridine hydrochloride (Aldrich, Taufkirchen, Germany). For stock solutions (10 mM), flupentixol, fluphenazine, thioridazine, levomepromazine and ondansetron (10 mM) were dissolved in aqua-bidest, while all other compounds were dissolved in ethanol. were cultured in minimum essential medium (MEM; Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS; Gibco), 1% glutamine, nonessential amino acids and antibiotics (Gibco) at 371C, 5% CO 2 and 95% humidity.
Murine N1E-115 cells were purchased from the European collection of cell cultures (ECACC, Salisbury, UK) and stored at À801C until further use. The cells were plated at a density of 10 5 cells/cm À2 onto plastic Petri dishes (Falcon) and were nourished with NaHCO 3 /HEPES-buffered MEM with 15% FCS and incubated at 371C with 5% CO 2 at 95% humidity. The medium was exchanged completely daily. Once every 3 days, cells were re-seeded onto fresh Petri dishes following treatment with trypsin-EDTA (1% in phosphate-buffered saline; PBS), resuspension in MEM and centrifugation at 200 Â g for 4 min. Serotonin-induced inward currents at N1E-115 cells are  well characterized as being mediated via the only  ionotropic serotonin receptor, namely the 5-HT 3  receptor (eg Malone et al  25 and Barann et al   26   ) , although the splice variants involved are not known.
Electrophysiological recordings 5-HT-induced inward Na þ currents were recorded from lifted HEK-5-HT 3A and N1E-115 cells in the whole-cell voltage-clamp configuration under visual control using an inverted microscope (Zeiss, Jena, Germany) as described previously. 27, 28 Cells were kept in a bath solution containing 140 mM NaCl, 2.8 mM KCl and 10 mM HEPES, pH 7.2. Patch electrodes were pulled from borosilicate glass (Hilgenberg, Malsfeld, Germany) using a horizontal pipette puller (ZeitzInstruments, Augsburg, Germany) to yield pipettes with a resistance of 3-6 MO. Pipettes were filled with a solution containing 130 mM CsCl, 2 mM MgCl 2 , 2 mM CaCl 2 , 2 mM ATP, 0.2 mM Tris-GTP, 10 mM glucose, 10 mM HEPES and 10 mM EGTA, pH 7.2. After the whole-cell configuration was established, the cells were lifted from the glass substrate and 10 mM serotonin (5-hydroxytryptamine, 5-HT) and/or drugs at the indicated concentrations were applied using a fast superfusion device. For control experiments, a piezo translator-driven double-barrelled application pipette was used to expose the lifted cell either to 5-HT-free or 5-HT-containing solution. A 2 s 5-HT pulse was delivered every 60 s. The stock solutions (10 mM or 10 mM) of the respective drugs were diluted with bath solution to the desired concentration. To control for any possible confounding solvent effects, currents were recorded with 0.1% ethanol in 5-HTfree or 5-HT-containing solutions. Current signals were recorded at a holding potential of À50 mV with an EPC-9 amplifier (Heka, Lamprecht, Germany) and were analysed using the Heka 8.5 PulseFit and IgorPro v.4.5 (Wavemetrics, Lake Oswego, OR, USA) software on a Power Macintosh G3 computer. Only results from stable cells entered the final analysis, that is, showing at least 50% recovery of responses to 5-HT following the removal of drugs. In some cells, recovery was not 100% because of rundown. To compensate for this effect, the % antagonism at each concentration was based on both the control and the recovery current by assuming a linear time course for the rundown.
Ca
2 þ measurements After harvesting, HEK-5-HT 3A cells were resuspended in Hank's balanced salt solution (HBSS; 137 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM CaCl 2 , 0.3 mM Na 2 HPO 4 , 6 mM glucose, 10 mM HEPES, pH 7.4) at a cell concentration of 10 7 cells/ml and loaded with fura-2-AM (Calbiochem, Bad Soden, Germany) at a final concentration of 3 mM by incubation for 30 min at 371C in the dark. This mixture was diluted 10-fold with fresh HBSS and incubated for another 10 min at room temperature in the dark. To remove external dye, the sample was centrifuged (300 Â g, 4 min) and resuspended in fresh HBSS to yield a final cell concentration of 10 7 cells/ml. The cytoplasmic-free Ca 2 þ concentration ([Ca 2 þ ] i ) was measured in cuvettes filled with 200 ml cell suspension and 1800 ml prewarmed HBSS (371C) using a fluorescence spectrometer LS50 (Perkin-Elmer, Ü berlingen, Germany). 5-HT was applied 40 s after the recording onset (total recording time 2 min). Drugs were applied in the cuvette at the indicated concentrations and preincubated for 2 min. To control for any possible confounding solvent effects, [Ca 2 þ ] i was recorded with 0.1% ethanol in the sample mixture. Throughout the recording, the mixture in the cuvette was continuously stirred and kept at 371C. Digitonin (50 mM) and EGTA (10 mM) were used to obtain R max and R min . 29 
Binding of [
3 H]GR65630 to membrane fractions of cells expressing the 5-HT 3 receptor HEK-5-HT 3A cells of 10 confluent plates (+ 10 cm) were harvested, washed twice with PBS and homogenized in 6 ml of 0.32 M sucrose, 50 mM Tris-HCl, 1 mM EDTA, pH 7.5. After centrifugation at 750 Â g for 10 min, the supernatant was recentrifugated at 100 000 Â g for 45 min. The resulting pellet was resuspended at 41C in 4-6 ml assay buffer (50 mM Tris-HCl, 1 mM EDTA, pH 7.5). The preparation of membrane fractions was performed at 41C. For ligandbinding experiments membrane fractions were incubated in microtiter plates in a total volume of 250 ml at 371C for 1 h with the indicated concentrations of [ 3 H]GR65630 (75 Ci/mmol; New England Nuclear, Boston, MA, USA). Bound ligand was separated from free ligand by washing with ice-cold assay buffer and rapid filtration through Whatman GF/B filters with a Titertek cell harvester (Nunc, Wiesbaden, Germany). Radioactivity was determined by liquid scintillation spectroscopy. Nonspecific binding was determined in the presence of 10 mM MDL 72222. Specific binding represented 80-94% of the total binding. Binding data were analysed with the EBDA and LIGAND programs, 30 which provide a nonlinear, least-squares regression analysis.
Preparation of purified plasma membranes HEK-5-HT 3A cells were harvested, washed twice with ice-cold PBS and resuspended in homogenization buffer (20 mM HEPES, 5 mM EDTA, pH 7.4). The suspension was thoroughly homogenized at 41C and centrifuged at 40 000 Â g for 30 min. The pelleted crude membrane was resuspended in ice-cold homogenization buffer and further purified by sucrose density-gradient centrifugation. For this purpose, 2 ml crude membrane preparation (approx. 10 mg protein) was layered on top of a stepwise gradient consisting of 3.5 ml of 60% (w/v) sucrose and 4 ml of 35% (w/v) sucrose prepared in homogenization buffer. After centrifugation at 11 500 Â g, 41C for 90 min (SW-41 rotor), the membranes at the upper 0-35% sucrose interface were collected and washed with homogenization buffer.
Measurement of steady-state anisotropy
Purified plasma membranes of HEK-5-HT 3A cells (50 mg of protein each) were resuspended in buffer (5 mM Tris, pH 7.0 and 25 mM NaCl) and labelled with the fluorophore 1,6-diphenyl-1,3,5-hexatriene (DPH) at a final concentration of 0.3 mM. Test substances (10 ml from a 100-fold stock solution) were added to 1 ml of the plasma membrane suspension and the steady-state measurements were performed after incubation for 1 h at 301C. For kinetic experiments, the membranes were incubated in a 1 ml cuvette at 301C for 3-5 min until a stable baseline fluorescence was obtained. Then, test compounds (10 ml) were added from a 100-fold stock solution and changes in fluorescence were monitored online. The membrane suspension was mixed continuously by a magnetic stirrer. Fluorescence intensity and polarization measurements were performed on a Quantamaster (PTI, Toronto, Canada) spectrofluorometer. The probe was excited at 362710 nm. Emission was measured at 430710 nm. A cutoff filter (GG 395) was placed in front of the emission filter to reduce light scattering. The steady-state fluorescence anisotropy, r, was determined as described previously. The frequent activation of 5-HT 3 receptors is accompanied by a constant rundown kinetics for peak (to 72.678.4% within 40 min, n ¼ 11), a pronounced acceleration of t des (to 56.1712.8%, within 40 min, n ¼ 11) and a reduction of the steady-state current (to 37.578.8% within 40 min, n ¼ 11). Simultaneous application of 5-HT and the competitive 5-HT 3 receptor antagonist ondansetron (1 nM for 2 s) reduced peak currents (to 86.878.5%, n ¼ 5) and to a lesser extent plateau currents (94.873.8%, n ¼ 5). These effects were far more pronounced following preincubation with the compound (Figure 1 ).
Antagonism of flupentixol on 5-HT-evoked currents
The thioxanthene flupentixol reduced inward Na þ -peak current responses evoked by 5-HT (10 mM for 2 s) with an IC 50 of 2.2470.06 mM (Figure 2b , Table  1 ) and showed an even higher potency on steady-state currents (Figure 2a and b, Table 1 ), reflecting the induction of a moderate receptor desensitization. Flupentixol had no significant effect on onset kinetics, desensitization or deactivation time constants ( Figure 7a , Table 1 ). The potencies against steady state, that is desensitized responses at the end of the 2 s application period are summarized in Table 1 .
The antagonism of flupentixol on the Ca 2 þ influx through the receptor channel, measured as a change in [Ca 2 þ ] i (Figure 2c ), was more pronounced than that Table 1 ).
The effect of the drug was voltage independent (Figure 3b) . Moreover, the effects on peak responses were more pronounced following preincubation with the compound (Figure 3a) . The blockade was apparently not use dependent (data not shown). These three characteristics argue against an open-channel blockade by flupentixol. When coapplied with 5-HT, the peak response was least affected and a characteristic 'tail' current occurred upon the removal of both 5-HT and flupentixol (Figure 3a) . These results Table 1 ). Haloperidol and levomepromazine also showed strong antagonistic effects on the 5-HTinduced Ca 2 þ currents, but were less effective on Na þ currents (Figure 5a and d, Table 1 ). Fluphenazine and thioridazine had a similar potency against peak and plateau currents, whereas levomepromazine and haloperidol were more potent on plateau currents ( Figure 5 , Table 1 ). In contrast, clozapine antagonized plateau currents less effectively ( Figure 6b , Table 1 ).
As described for flupentixol, the effects of fluphenazine, thioridazine, levomepromazine and haloperidol were voltage independent and more pronounced following preincubation with the compound. When coapplied with 5-HT, the response also showed a 'tail' current after the removal of both 5-HT and antagonist (data not shown). However, no such 'tail' currents occurred after application of clozapine (Figure 6c ). Representative currents in Figure 7 show the effects on kinetics for all compounds tested. In contrast to Figure 4 Molecule structure of neuroleptics.
Antipsychotic drugs and 5-HT 3 receptors G Rammes et al the other neuroleptics, risperidone exerted only a slight antagonism and reduced peak currents to 76.874.6%, with no effect on receptor kinetics even at a concentration of 100 mM (Figure 7g ). Fluphenazine and levomepromazine reduced the Ca 2 þ influx with similar potency (Figure 5a and c A similar antagonism of neuroleptics against cation currents has been obtained with endogenous 5-HT 3 receptors of murine N1E-115 neuroblastoma cells ( Figure 8 , Table 2 ). Levomepromazine, haloperidol and flupentixol were slightly more potent at endogenous 5-HT 3 Figure 9 ). Therefore, the antagonism of flupentixol, fluphenazine, haloperidol, levomepromazine and thioridazine is mediated by a mechanism different from that achieved with competitive 5-HT 3A receptor antagonists, which is also supported by the electrophysiological data (see above). Steady-state anisotropy To detect eventual effects of different neuroleptics on the physicochemical properties of the plasma membrane, we measured the steady-state anisotropy of DPH-labelled purified plasma membranes of HEK-5-HT 3A cells. Application of fluphenazine, thioridazine, levomepromazine and clozapine (1-100 mM) increased the anisotropy of the fluorescence probe DPH, while flupentixol and haloperidol decreased anisotropy within seconds in a dose-dependent manner (Table 3) . However, only fluphenazine elicited significant changes in anisotropy at concentrations less than 10 mM. Using linear regression analysis, we found no correlation of the neuroleptics-induced changes in anisotropy and their antagonistic effects on the 5-HT-evoked Na þ current (coefficient r 2 ¼ 0.2175).
Function-structure relationship
The effects of various tricyclic compounds on the 5-HT-evoked Na þ -peak current, -plateau current and [Ca 2 þ ] i increase were tested to identify the structural components of neuroleptics that contribute to an antagonistic activity at the 5-HT 3A receptor ( Figure  10 ).
2-(trifluoromethyl)-phenothiazine (2-TFMP; 10 mM; Figure 10 ), the tricyclic core of flupentixol and fluphenazine (Figure 4 ) without an aliphatic side chain, showed less inhibitory effects on Na þ -peak current, -plateau current and Ca 2 þ influx than flupentixol and fluphenazine, applied at the same concentration ( Figure 10) . Thus, the aliphatic side chain seems to modulate the functional antagonism of neuroleptics at the 5-HT 3A receptor. To investigate whether the trifluoromethyl group of the outer ring affects the antagonistic activity of tricyclic compounds at the 5-HT 3A receptor, we tested the effects of phenothiazine (Figure 10 ) on the 5-HT-evoked Na þ current and [Ca 2 þ ] i increase. Phenothiazine (10 mM) reduced peak currents to 61.473.8% and showed a comparable, weak potency on plateau currents as 2-TFMP ( Figure 10) . However, the absence of the trifluoromethyl group strongly increased the antagonism on 5-HT-induced Ca 2 þ influx through 5-HT 3A receptors. Acridine, where the sulphur atom in the middle ring is replaced by a carbon atom, displayed similar antagonistic effects as phenothiazine ( Figure  10 ). Conclusively, these results suggest that the aliphatic side chain plays a role for a potent antagonism at both Na þ and Ca 2 þ currents. Further removal of the trifluoromethyl group reinduces a potent antagonism against Ca 2 þ ions but not against Na þ ions.
Discussion
In the present study, we investigated the interaction of various neuroleptics with 5-HT 3 receptor-mediated signalling. These experiments demonstrate a potent noncompetitive antagonism of phenothiazines, thioxanthenes and butyrophenones against Na þ and Ca fluidity might contribute to their antagonistic effect at the 5-HT 3 receptor. Using analogues of flupentixol and fluphenazine, we found that the lipophilic side chain may play a role for a potent antagonism against Na þ and Ca 2 þ currents. The antagonistic effects of neuroleptics on 5-HT 3 receptors are similar to those previously reported for different types of antidepressants. 32, 33 These antagonistic effects are mainly reflected by a reduction of peak and plateau of the Na þ currents. While for thioridazine and fluphenazine the IC 50 values for peak and plateau currents are similar, the antagonistic action of flupentixol, levomepromazine and haloperidol is more potent against plateau currents ( Figure 5 , Table 1 ), demonstrating that they antagonize responses by inducing desensitization. It seems rather unlikely that an open-channel blockade contributes to the 5-HT 3A receptor antagonistic effects of the neuroleptics investigated. The effects of all compounds were voltage-independent and already a pre-exposure of the receptor to these neuroleptics reduced the 5-HT-evoked response, indicating that they did not need to access an open-channel pore to inhibit the ion flux.
Only the atypical neuroleptic clozapine displaced the selective competitive 5-HT 3 receptor antagonist [ 3 H]GR65630 from the 5-HT binding site ( Figure 9 ). In line with such a competitive antagonistic action, the effect of clozapine is mainly reflected by the reduction of the peak current, comparable to the effect of the competitive 5-HT 3 receptor antagonist ondansetron. Functional antagonistic properties of clozapine have also been reported previously for endogenous rat and recombinant mouse 5-HT 3A receptors with even higher potency 22, 23 compared to recombinant human 5-HT 3A receptors in the present study. Fluphenazine, levomepromazine and haloperidol antagonized the 5-HT-evoked cation current by an interaction with two sites of the 5-HT 3A receptor reflected by a Hill coefficient near À0.5, whereas flupentixol, thioridazine and clozapine yielded Hill coefficients of À0.73 to À1.14 ( Table 1) , suggesting an antagonism mediated by an interaction at a single site. Flupentixol, fluphenazine, thioridazine, levomepromazine and clozapine had almost no effect on the kinetics of the 5-HT 3A receptor-mediated currents. Haloperidol markedly decreased the time constant of receptor desensitization, which could account for the relatively greater potency against plateau currents. In To delineate effects of neuroleptics on the kinetics of 5-HTevoked Na þ current, the reduced peak amplitude was adjusted to the control peak (right panels). The upper bar indicates the application of 10 mM 5-HT, the lower bar indicates the presence of the respective neuroleptics at their IC 50 concentration ( Figure 5 , Table 1 ), with the exception of risperidone, where 100 mM were used.
contrast to the other neuroleptics studied, risperidone exerted only slight antagonistic effects against 5-HT 3A receptor currents at high concentrations (Figure 7g ).
Noncompetitive modulation of ion channel activity may arise from interactions with the receptor-lipid interface, 34 for example, by changing membrane fluidity. Different types of antidepressants increase membrane fluidity at low to upper micromolar concentrations; however, this effect does not markedly account for their functional antagonistic action at 5-HT 3 receptors. 33 In the present study, flupentixol and haloperidol also increased membrane fluidity as reflected by a decrease in DPH fluorescence anisotropy, while fluphenazine, thioridazine, levomepromazine and clozapine decreased membrane fluidity (Table 3) . Only fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC 50 values against peak currents, indicating that a change in membrane anisotropy might contribute to their functional antagonistic effect at the 5-HT 3 receptor to some extent. Thus, the inhibitory effects of flupentixol, thioridazine, levomepromazine and clozapine at this ligand-gated ion channel are probably not mediated by their effect on membrane fluidity.
The antagonistic actions of flupentixol, fluphenazine and presumably also of thioridazine and levomepromazine at the 5-HT 3A receptor may be partly attributed to their N/C-bound side chains of the central ring, because the antagonistic potency decreases with the removal of these side chains ( Figure  10) . Interestingly, the removal of the trifluoromethyl group differentially affects Na þ and Ca 2 þ currents evoked by 5-HT. Homomeric 5-HT 3A receptors are more permeable to Ca 2 þ ions than heteromeric 5-HT 3A /5-HT 3B receptors. 35 Anionic residues in the channel pore of the 5-HT 3B subunit probably control Ca 2 þ permeability of heteromeric 5-HT 3A /5-HT 3B receptors. As such, the differential modulation of Na þ and Ca 2 þ currents through 5-HT 3A receptors by noncompetitive antagonists might be related to an alteration of the steric orientation of charges near the channel pore.
Besides their inhibitory effects on Na þ currents, with the exception of fluphenazine, all substances showed a higher potency against 5-HT 3A receptormediated Ca 2 þ currents with IC 50 values between 120 nM and 2.19 mM ( Figure 5 , Table 1 It has to be considered that the effects of neuroleptics at the 5-HT 3 receptor are not specific for this ligand-gated ion channel. Various neuroleptics such as clozapine, zotepine and olanzapine have recently been shown to act as functional antagonists at GABA A receptors. 37 Moreover, various antipsychotic phenothiazines may block calcium-activated potassium channels at micromolar concentrations. 38 In addition, neuroleptics have also been demonstrated to inhibit voltage-gated potassium channels 39 or T-type calcium channels. 40 Thus, the modulation of various ion channels by neuroleptics may contribute to both the clinical effects and the side effect profile of distinct antipsychotic drugs.
The functional antagonism of neuroleptics at the 5-HT 3 receptor may have important physiological implications. In the CNS, the functional properties of presynaptic 5-HT 3 receptors might differ from those of postsynaptic 5-HT 3 receptors. Presynaptic 5-HT 3 receptors are responsible for the elevation of intracellular Ca 2 þ 3 and modulate the release of several neurotransmitters, such as glutamate, dopamine, GABA, norepinephrine and 5-HT.
2,10,41 Postsynaptic 5-HT 3 receptors mediate fast synaptic neurotransmission in the CNS. 4 The reduction of these Na þ and Ca 2 þ fluxes by antipsychotics may be involved in their inhibitory effect on neuronal discharge activity and modulation of postsynaptic 5-HT 3 receptors could alter learning and memory processes. 41 Indeed, 5-HT 3 receptor antagonists facilitate cognitive processes 1 and seem to have procognitive effects during ageing. 7, 42, 43 The inhibitory effects of neuroleptics at 5-HT 3 receptors might contribute to the antipsychotic potential of these compounds, as 5-HT 3 receptor antagonists reduce dopaminergic neurotransmission (see, for review, Costall et al. ). Indeed, first clinical investigations suggested an anxiolytic and antipsychotic potency of specific 5-HT 3 receptor antagonists. 1, 11, 12 However, systematic clinical studies could not demonstrate sufficient antipsychotic effects of selective 5-HT 3 receptor antagonists in schizophrenia. 11, 12, 20, 44 Nevertheless, the 5-HT 3 receptor antagonistic properties might contribute to the pharmacological profile of distinct neuroleptics.
The concentrations necessary for the antagonistic potencies against 5-HT-evoked Na þ and Ca 2 þ fluxes are within the range of concentrations of antipsychotics reached in rat brain tissue after acute or chronic application, [45] [46] [47] [48] and thus appear to be of therapeutical relevance. Furthermore, haloperidol concentrations in the range between 8.9 and 226 mM have been shown in human post-mortem brain tissue. 49 In conclusion, various types of neuroleptics at therapeutic concentrations act as noncompetitive antagonists at the 5-HT 3 receptor. This effect, therefore, may contribute to the antipsychotic efficacy of such compounds and may constitute a not yet recognized pharmacological principle of neuroleptics.
